Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …

Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …

Background With the introduction of new anti-tuberculosis drugs, all-oral regimens with
shorter treatment durations for multidrug-resistant tuberculosis have been anticipated. We …

We sought to compare the effectiveness of two World Health Organization (WHO)-
recommended regimens for the treatment of rifampin-or multidrug-resistant (RR/MDR) …

Background Linezolid was recently re‐classified as a Group A drug by the World Health
Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and …

Little is known about the impact of comorbidities on multidrug resistant (MDR) and
extensively drug resistant (XDR) tuberculosis (TB) treatment outcomes. We aimed to …

Background Public–private mix (PPM) programs on tuberculosis (TB) have a critical role in
engaging and integrating the private sector into the national TB control efforts in order to …

Background In 2014 only 50% of multidrug-resistant tuberculosis (MDR-TB) patients
achieved a successful treatment outcome. With limited options for medical treatment, surgery …

Abstract Purpose The Korea Centers for Disease Control & Prevention has implemented a
review process for the approval of new drugs used to treat patients with multidrug-resistant …

SETTING: Studies have shown that linezolid (LZD) can be used to treat extensively drug-
resistant tuberculosis (XDR-TB). OBJECTIVE: To conduct a systematic review and meta …